文献速递消化道肿瘤与早癌炎症性肠病

胃肠道肿瘤或炎症性肠病患者的流感和肺炎球菌疫苗接种:一项提高接种覆盖率方法的前瞻性队列研究

Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage.
PubMed 文献 · Aliment Pharmacol Ther · 2018-11-28

这项在Nancy大学医院开展的前瞻性队列研究纳入366例胃肠道肿瘤(GC=99)或炎症性肠病(IBD=267)门诊患者,评估专科感染病咨询对疫苗接种覆盖率的影响。基线流感疫苗接种率为34.7%、肺炎球菌疫苗为14.5%,约43%患者担心疫苗副作用。参加专科咨询的102例中87.3%接种了新疫苗,GC患者肺炎球菌疫苗接种率从10.1%升至87.5%,IBD患者从16.1%升至85.7%。

要点

  • GC和IBD患者基线的流感疫苗接种率为34.7%、肺炎球菌疫苗为14.5%。
  • 约43%的患者担心疫苗副作用,是接种的主要障碍之一。
  • 专科感染病咨询后GC患者肺炎球菌疫苗接种率从10.1%升至87.5%,IBD患者从16.1%升至85.7%。

核心结论

  • 专科感染病咨询可提高GC和IBD患者对疫苗接种的知识和疫苗接种覆盖率,该方法可应用于所有高危人群。

研究设计与样本

  • 2016年12月至2017年4月在Nancy大学医院消化科门诊开展的前瞻性队列研究,纳入所有GC或IBD患者共366例(GC=99,IBD=267),实施三阶段疫苗接种计划。

主要发现

  • 基线疫苗接种率为流感34.7%、肺炎球菌14.5%,约43%的患者担心疫苗副作用。
  • 初始问卷后49.3%有兴趣的患者参加了专科疫苗接种咨询(n=102)。
  • 参加咨询者中87.3%(n=89)接种了新疫苗,41.2%改变了对疫苗接种的想法,92.2%会向其他患者推荐该计划。
  • 接种疫苗的患者中97.8%(n=87)接种了肺炎球菌疫苗、40.4%接种了破伤风-白喉-脊髓灰质炎疫苗、7.9%接种了流感疫苗。
  • GC患者专科咨询后抗肺炎球菌疫苗接种率为87.5%,咨询前为10.1%;IBD患者相应为85.7%和16.1%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although influenza and pneumococcal vaccinations for high-risk populations are recommended by current guidelines, vaccination coverage is low in patients with gastrointestinal cancer (GC) or inflammatory bowel disease (IBD). AIM: To evaluate the impact of a specialised infectious disease consultation on vaccination coverage rates in these patients. METHODS: Between December 2016 and April 2017, all patients with GC or IBD followed in the outpatient clinic of the Gastroenterology department at the Nancy University Hospital enrolled in a 3-phase vaccination programme. Phase 1: Initial questionnaire (vaccination status, knowledge about vaccines and possible barriers to vaccination); Phase 2: Infectious disease consultation; Phase 3: Subsequent questionnaire (evolution of patients' knowledge about vaccination). RESULTS: A total of 366 patients were included (GC = 99, IBD = 267). Vaccination rate was 34.7% for influenza and 14.5% for pneumococcus. About 43% of the patients feared side effects of vaccines. After the initial questionnaire, 49.3% of the interested patients participated in a specialised vaccination consultation (n = 102). 87.3% (n = 89) received new vaccination, 41.2% changed their mind about vaccination, and 92.2% would recommend this programme to other patients. Among vaccinated patients, 97.8% (n = 87) received pneumococcal vaccine, 40.4% received tetanus-diphtheria-polio vaccine, and 7.9% received influenza vaccine. In GC patients, anti-pneumococcal vaccination rate was 87.5% after the specialised consultation compared with 10.1% before. In IBD patients, corresponding rates were 85.7% and 16.1%. CONCLUSIONS: A specialised infectious disease consultation can improve GC and IBD patients' knowledge about vaccination and vaccination coverage. This approach could be applied to all high-risk populations.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sitte J, Frentiu E, Baumann C, et al. Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage. Aliment Pharmacol Ther. 2018. PMID: 30485467. doi:10.1111/apt.15057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。